Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALV 
Kalvista Pharmaceuticals Inc (KALV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KALV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.67
1 Year Target Price $31.67
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.24% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 680.09M USD | Price to earnings Ratio - | 1Y Target Price 31.67 |
Price to earnings Ratio - | 1Y Target Price 31.67 | ||
Volume (30-day avg) 10 | Beta 0.04 | 52 Weeks Range 7.30 - 16.32 | Updated Date 08/29/2025 |
52 Weeks Range 7.30 - 16.32 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.69 |
Earnings Date
Report Date 2025-09-03 | When Before Market | Estimate -0.9 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.33% | Return on Equity (TTM) -121.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 465781008 | Price to Sales(TTM) 107.42 |
Enterprise Value 465781008 | Price to Sales(TTM) 107.42 | ||
Enterprise Value to Revenue 76.33 | Enterprise Value to EBITDA -3.53 | Shares Outstanding 50339800 | Shares Floating 27926638 |
Shares Outstanding 50339800 | Shares Floating 27926638 | ||
Percent Insiders 1.27 | Percent Institutions 109.78 |
Upturn AI SWOT
Kalvista Pharmaceuticals Inc
Company Overview
History and Background
Kalvista Pharmaceuticals Inc. is a pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors to treat diseases with significant unmet needs. Founded in 2011, it has focused primarily on hereditary angioedema (HAE) and diabetic macular edema (DME). It has evolved through clinical trials and strategic partnerships.
Core Business Areas
- HAE Program: Development of oral therapies for hereditary angioedema. This is its primary focus.
Leadership and Structure
Kalvista has a leadership team consisting of a CEO, CFO, and other executives responsible for research, development, and commercialization strategies. The company operates with a typical biotech organizational structure, emphasizing R&D.
Top Products and Market Share
Key Offerings
- Sebetralstat: Oral on-demand treatment for HAE attacks. Currently in Phase 3 trials. Market competitors include injectable therapies from Takeda (TAK), CSL Behring (CSL), and BioCryst (BCRX). Market share data not yet available as the product is not yet approved.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments required for R&D and clinical trials. The market for rare diseases like HAE is growing, driven by increased awareness and improved diagnosis.
Positioning
Kalvista is positioned as a developer of oral HAE therapies, offering a more convenient alternative to existing injectable treatments. Their competitive advantage lies in their focus on oral protease inhibitors.
Total Addressable Market (TAM)
The global HAE market is estimated to be several billion dollars. Kalvista is positioned to capture a significant portion of this TAM with a successful oral therapy.
Upturn SWOT Analysis
Strengths
- Novel oral therapies
- Strong intellectual property
- Experienced management team
- Targeting unmet need in HAE
Weaknesses
- Reliance on single product pipeline
- Clinical trial risk
- Limited commercial infrastructure
- Cash burn rate
Opportunities
- Expansion to other indications
- Strategic partnerships
- Acquisition by larger pharmaceutical company
- Positive clinical trial results
Threats
- Competition from existing therapies
- Regulatory hurdles
- Patent challenges
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- TAK
- CSL
- BCRX
Competitive Landscape
Kalvista faces competition from established players with marketed HAE therapies. Their advantage lies in developing a convenient oral treatment, but they must demonstrate comparable efficacy and safety to injectable options.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and strategic collaborations. There has not been substantial revenue growth as the company is pre-commercial.
Future Projections: Future growth is dependent on the successful development and commercialization of sebetralstat. Analyst projections will vary based on the perceived probability of success and market penetration.
Recent Initiatives: Recent initiatives include advancing sebetralstat through Phase 3 clinical trials and exploring potential partnerships for commercialization.
Summary
Kalvista Pharmaceuticals is a pre-commercial biopharmaceutical company focused on oral HAE treatments, primarily sebetralstat. Successful Phase 3 results are crucial for future growth. The main risks stem from clinical trial outcomes and competition from existing HAE therapies. Kalvista presents opportunity with an oral treatment if safety and efficacy are strong.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kalvista Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-04-09 | CEO & Director Mr. Benjamin L. Palleiko | ||
Sector Healthcare | Industry Biotechnology | Full time employees 270 | Website https://www.kalvista.com |
Full time employees 270 | Website https://www.kalvista.com | ||
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.